AFA
DRNA

Abacus FCF Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Abacus FCF Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-18,314
Closed -$441K – 169
2021
Q1 		$441K Buy
+18,314
New +$468K 0.22% 144

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Abacus FCF Advisors's DRNA Position: Q2 2021 in Review

Abacus FCF Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2021, closing a stake of 18,314 shares — an estimated $441K sold.

Abacus FCF Advisors first reported a position in DRNA in Q1 2021 and held it in 1 quarter. The position peaked at $441K in Q1 2021. 203 funds tracked by Wall St. Rank hold DRNA as of Q2 2021.

  • Abacus FCF Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Abacus FCF Advisors sold 18,314 Dicerna Pharmaceuticals, Inc. shares in Q2 2021, an estimated $441K.
  • Abacus FCF Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Abacus FCF Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $441K in Q1 2021.
  • 203 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2021.

Based on Abacus FCF Advisors's 13F filing for Q2 2021, filed 30 Jul 2021.